No CRS summary available for this bill.
This section sets forth congressional findings on the human papillomavirus (HPV), including that it causes approximately 39,300 cancer cases annually across six types (91% of cervical and anal cancers; 70% of oropharyngeal cancers, which are over twice as common in men); Black and Hispanic women face higher cervical cancer rates due to screening disparities; cervical cancer screening has declined with more distant-stage diagnoses; HPV vaccines prevent most cancer-causing infections (as well as recurrent respiratory papillomatosis and warts), are most effective at ages 9-12 (licensed through age 45 for both sexes), and have a 63% adolescent series completion rate (lower in rural areas), with provider recommendations critical to uptake.
This section establishes a national public awareness campaign on human papillomavirus (HPV) cancer prevention, to be conducted by the Secretary of Health and Human Services (HHS), acting through the Director of the Centers for Disease Control and Prevention (CDC). The campaign must (1) increase awareness of HPV vaccination to prevent HPV-associated cancers, combat misinformation, and raise vaccination rates and series completion; (2) use evidence-based media and public engagement through competitive grants or cooperative agreements to nonprofit entities; (3) develop culturally and linguistically competent resources tailored for communities with high unvaccinated rates (including males), high rates of cervical or other HPV-associated cancers (e.g., Black and Hispanic women), oropharynx cancers (e.g., active-duty service members and veterans), and rural areas; (4) disseminate information to health care providers, facilities, public health departments, schools, and colleges; (5) coordinate with other federal HPV vaccination and screening efforts; (6) conduct message testing; and (7) award grants to state, local, and Tribal public health departments for community engagement and dissemination of National Breast and Cervical Cancer Early Detection Program resources. Campaign dissemination may use social media, television, radio, internet, public communications, and trusted figures, with messaging on recommended vaccination ages, benefits, and safety monitoring. The section authorizes $5 million for each of FY2026 through FY2030 and requires HHS to submit to specified congressional committees, by September 30, 2027, a report with a qualitative assessment of the campaign and its impact on HPV-associated cancers.
This section (1) authorizes $300 million for each of FY2026 through FY2030 for the Breast and Cervical Cancer Early Detection Program (previously authorized through FY2012, including $275 million for FY2012); and (2) extends the coordinating committee on breast and cervical cancer screening through 2030 (from 2020). The program provides CDC grants to states for breast and cervical cancer screening of low-income uninsured or underinsured women, treatment referrals, public education, health professional training, quality monitoring, and program evaluation.